Skip Navigation



Annals of Oncology Advance Access published online on December 16, 2008
Annals of Oncology, doi:10.1093/annonc/mdn674
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/3/486    most recent
mdn674v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by de Boer, R.
Right arrow Articles by Vansteenkiste, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Boer, R.
Right arrow Articles by Vansteenkiste, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer

R. de Boer1,*, Y. Humblet2, J. Wolf3, L. Nogová3, K. Ruffert4, T. Milenkova5, R. Smith5, A. Godwood6 and J. Vansteenkiste7

1 Department of Medical Oncology, Western Hospital, Melbourne, Australia
2 Department of Medical Oncology, St Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium
3 Department of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne
4 Clinic and General Practice of Internal Medicine/Hematology/Oncology, Jena, Germany
5 AstraZeneca, Alderley Park, Cheshire
6 AstraZeneca, Charnwood, Leicestershire, UK
7 University Hospital Leuven, Leuven, Belgium

* Correspondence to: Dr R. de Boer, Department of Medical Oncology, Western Hospital, Gordon Street, Footscray, Victoria 3011, Australia. Tel: +3-8345-6060; Fax: +3-9347-7508; E-mail: richard.deboer{at}wh.org.au

Background: Vandetanib (ZACTIMATM; ZD6474) is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. The safety and tolerability of vandetanib plus pemetrexed was assessed in patients with advanced non-small-cell lung cancer (NSCLC).

Patients and methods: Patients with previously treated NSCLC (stage IIIB/IV) received once-daily oral vandetanib (100 or 300 mg) with pemetrexed (500 mg/m2 i.v. infusion every 21 days).

Results: Patients received vandetanib 100 mg + pemetrexed (n = 10) or vandetanib 300 mg + pemetrexed (n = 11). The protocol definition of a tolerable dose [vandetanib-related dose-limiting toxicity (DLT) in less than 2 patients] was met in both dose cohorts, with one DLT reported in each: asymptomatic QTc prolongation (>100 ms increase from baseline, but absolute QTc <500 ms) in the 100 mg cohort and interstitial lung disease, which resolved after steroid therapy, in the 300 mg cohort. The most common adverse events were rash, anorexia, fatigue and diarrhea (all n = 10).

Conclusion: Vandetanib and pemetrexed in combination were generally well tolerated in patients with advanced NSCLC.

Angiogenesis, EGFR, advanced NSCLC, pemetrexed, vandetanib

Received for publication June 22, 2008. Revision received September 9, 2008. Accepted for publication September 10, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
A. Morabito, M. C. Piccirillo, F. Falasconi, G. De Feo, A. Del Giudice, J. Bryce, M. Di Maio, E. De Maio, N. Normanno, and F. Perrone
Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
Oncologist, April 1, 2009; 14(4): 378 - 390.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.